Ampligen

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs April 6.) Forty Seven Inc (NASDAQ: FTSV) Masimo Corporation (NASDAQ: MASI) Seattle Genetics, Inc. (NASDAQ: SGEN) Vertex Pharmaceuticals Incorporated (...

Hemispherx BioPharma, Inc (NYSE: HEB) is a nano-cap biopharmaceutical research and development company that focuses on the treatment of seriously debilitating disorders. Its flagship products include Alferon N Injection, Ampligen and Alferon LDO. Benzinga recently had the chance to speak with the...

Hemispherx BioPharma, Inc (NYSE: HEB) is a nano-cap biopharmaceutical research and development company that focuses on the treatment of seriously debilitating disorders. Its flagship products include Alferon N Injection, Ampligen and Alferon LDO. Benzinga recently had the chance to speak with the...

The news was mediocre at best, yet Hemispherx BioPharma, Inc. (AMEX: HEB) shares are up a solid 12% after the company announced a response to issues raised regarding Ampligen as a treatment for chronic fatigue syndrome. The FDA, in simplest terms, needed more information about the drug's...